PubMed

Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study.

Rossing K, Christensen PK, Hansen BV, Carstensen B, Parving HH.

Diabetes Care. 2003 Jan;26(1):150-5.PMID: 12502672 [PubMed - indexed for MEDLINE]Related articlesFree article

Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial.

Rossing K, Jacobsen P, Pietraszek L, Parving HH.

Diabetes Care. 2003 Aug;26(8):2268-74.PMID: 12882847 [PubMed - indexed for MEDLINE]Related articlesFree article

Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study.

Rossing K, Christensen PK, Jensen BR, Parving HH.

Diabetes Care. 2002 Jan;25(1):95-100.PMID: 11772908 [PubMed - indexed for MEDLINE]Related articlesFree article

Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria.

Rossing K, Schjoedt KJ, Jensen BR, Boomsma F, Parving HH.

Kidney Int. 2005 Sep;68(3):1190-8.PMID: 16105050 [PubMed - indexed for MEDLINE]Related articles

Autoregulated glomerular filtration rate during candesartan treatment in hypertensive type 2 diabetic patients.

Christensen PK, Lund S, Parving HH.

Kidney Int. 2001 Oct;60(4):1435-42.PMID: 11576357 [PubMed - indexed for MEDLINE]Related articlesFree article

Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study.

Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH.

Diabetes Care. 2005 Sep;28(9):2106-12.PMID: 16123474 [PubMed - indexed for MEDLINE]Related articlesFree article

Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial.

Schjoedt KJ, Astrup AS, Persson F, Frandsen E, Boomsma F, Rossing K, Tarnow L, Rossing P, Parving HH.

Diabetologia. 2009 Jan;52(1):46-9. Epub 2008 Oct 31.PMID: 18974967 [PubMed - indexed for MEDLINE]Related articles

Optimal dose of losartan for renoprotection in diabetic nephropathy.

Andersen S, Rossing P, Juhl TR, Deinum J, Parving HH.

Nephrol Dial Transplant. 2002 Aug;17(8):1413-8.PMID: 12147788 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.

Song JH, Cha SH, Lee HJ, Lee SW, Park GH, Lee SW, Kim MJ.

Nephrol Dial Transplant. 2006 Mar;21(3):683-9. Epub 2005 Dec 5.PMID: 16330466 [PubMed - indexed for MEDLINE]Related articlesFree article

Targeting albumin excretion rate in the treatment of the hypertensive diabetic patient with renal disease.

Krimholtz MJ, Karalliedde J, Thomas S, Bilous R, Viberti G.

J Am Soc Nephrol. 2005 Mar;16 Suppl 1:S42-7.PMID: 15938033 [PubMed - indexed for MEDLINE]Related articlesFree article

Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.

Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH.

Kidney Int. 2003 May;63(5):1874-80.PMID: 12675866 [PubMed - indexed for MEDLINE]Related articles

Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.

Jacobsen P, Andersen S, Jensen BR, Parving HH.

J Am Soc Nephrol. 2003 Apr;14(4):992-9.PMID: 12660333 [PubMed - indexed for MEDLINE]Related articlesFree article

Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment.

Rossing P, Tarnow L, Boelskifte S, Jensen BR, Nielsen FS, Parving HH.

Diabetes. 1997 Mar;46(3):481-7.PMID: 9032106 [PubMed - indexed for MEDLINE]Related articles

Autoregulation of glomerular filtration rate in patients with type 2 diabetes during isradipine therapy.

Christensen PK, Akram K, Kønig KB, Parving HH.

Diabetes Care. 2003 Jan;26(1):156-62.PMID: 12502673 [PubMed - indexed for MEDLINE]Related articlesFree article

Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy.

Jacobsen P, Andersen S, Rossing K, Hansen BV, Parving HH.

Nephrol Dial Transplant. 2002 Jun;17(6):1019-24.PMID: 12032191 [PubMed - indexed for MEDLINE]Related articlesFree article

Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy.

Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Tarnow L, Rossing P, Parving HH.

Kidney Int. 2006 Aug;70(3):536-42. Epub 2006 Jun 14.PMID: 16775595 [PubMed - indexed for MEDLINE]Related articles

Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.

Galle J, Schwedhelm E, Pinnetti S, Böger RH, Wanner C; VIVALDI investigators.

Nephrol Dial Transplant. 2008 Oct;23(10):3174-83. Epub 2008 May 1.PMID: 18450829 [PubMed - indexed for MEDLINE]Related articles

Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy.

Fujisawa T, Ikegami H, Ono M, Nishino M, Noso S, Kawabata Y, Ogihara T.

Am J Hypertens. 2005 Jan;18(1):13-7.PMID: 15691611 [PubMed - indexed for MEDLINE]Related articles

Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy.

Tarnow L, Rossing P, Jensen C, Hansen BV, Parving HH.

Diabetes Care. 2000 Dec;23(12):1725-30.PMID: 11128341 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy.

Sato A, Tabata M, Hayashi K, Saruta T.

Clin Exp Nephrol. 2003 Sep;7(3):215-20.PMID: 14586718 [PubMed - indexed for MEDLINE]Related articles